Cambridge Cancer Genomics went through Y Combinator in the Summer 2017 batch, describing itself as CCG.ai empowers clinicians to make personalised treatment strategies…. Y Combinator's company directory lists it as Inactive. The directory does not say why a company stopped, and this page does not guess.
- Batch
- Summer 2017
- What they did
- CCG.ai empowers clinicians to make personalised treatment strategies…
- Industry
- Healthcare
- Team size
- 25
- Based
- Cambridge, England, United Kingdom; England, United Kingdom
- Status
- Inactive, as listed by Y Combinator
Its batch
Summer 2017 had 125 companies in YC's listing: 56 Active, 33 Acquired, 1 Public and 35 Inactive, so Cambridge Cancer Genomics is one of 35 companies from that batch listed as Inactive (28%). Across YC batches at least two years old, 23% of companies are listed Inactive.
Statuses are Y Combinator's own listing in its public company directory, read on the date shown. YC's directory can drop companies altogether, so the Inactive counts here are a floor, not a full count of companies that stopped. Acquired and Public are as YC lists them; neither says anything about the price or the outcome for founders.
The record: Cambridge Cancer Genomics in the Y Combinator directory. Measured 2026-09-26 from Y Combinator's company directory.
YC Summer 2017All shut-down YC companiesYC outcomes
Tools for this story
Each opens in a new tab, filled in for Cambridge Cancer Genomics. With no account yet, you sign up free and land on the result.